PriceTargets.com logo

Corcept Therapeutics - CORT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $72.17
  • Forecasted Upside: 40.35%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$51.42 As of 05/1/2026 05:00 PM ET
▲ +4.9 (10.53%)

This chart shows the closing price for CORT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Corcept Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CORT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CORT

Analyst Price Target is $72.17
▲ +40.35% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is $72.17, with a high forecast of $110.00 and a low forecast of $30.00. The average price target represents a 40.35% upside from the last price of $51.42.

This chart shows the closing price for CORT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 contributing investment analysts is to moderate buy stock in Corcept Therapeutics. This rating has held steady since March 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
2/2/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/3/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/1/2026Piper SandlerBoost TargetOverweight ➝ Overweight$73.00 ➝ $88.00
3/26/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$100.00 ➝ $110.00
3/26/2026Wolfe ResearchUpgradeUnderperform ➝ Peer Perform
3/25/2026Truist FinancialUpgradeStrong-Buy
3/25/2026HC WainwrightLower TargetBuy ➝ Buy$67.00 ➝ $60.00
2/20/2026HC WainwrightLower TargetBuy ➝ Buy$105.00 ➝ $67.00
1/23/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$99.00 ➝ $100.00
1/22/2026HC WainwrightBoost TargetBuy ➝ Buy$90.00 ➝ $105.00
1/13/2026Zacks ResearchDowngradeHold ➝ Strong Sell
1/2/2026HC WainwrightLower TargetBuy ➝ Buy$145.00 ➝ $90.00
1/2/2026Canaccord Genuity GroupLower TargetBuy ➝ Buy$140.00 ➝ $99.00
12/31/2025Truist FinancialSet Target$50.00
12/31/2025Wolfe ResearchDowngradePeer Perform ➝ Underperform$30.00
12/29/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/22/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/16/2025UBS GroupInitiated CoverageNeutral$95.00
12/16/2025UBS GroupInitiated CoverageHold$95.00
12/15/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/15/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
12/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/1/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/25/2025HC WainwrightReiterated RatingBuy ➝ Buy$145.00
11/19/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/18/2025Wolfe ResearchInitiated CoveragePeer Perform
11/13/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
10/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$145.00
10/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$145.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/1/2025Zacks ResearchDowngradeHold ➝ Strong Sell
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/25/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$140.00
9/10/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$137.00 ➝ $140.00
8/1/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$142.00 ➝ $137.00
8/1/2025Piper SandlerLower TargetOverweight ➝ Overweight$131.00 ➝ $121.00
5/6/2025Truist FinancialSet Target$135.00
5/6/2025HC WainwrightLower TargetBuy ➝ Buy$150.00 ➝ $145.00
4/3/2025Piper SandlerBoost TargetOverweight ➝ Overweight$128.00 ➝ $131.00
4/1/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$130.00 ➝ $142.00
3/31/2025Truist FinancialBoost TargetBuy ➝ Buy$76.00 ➝ $150.00
3/31/2025HC WainwrightBoost TargetBuy ➝ Buy$115.00 ➝ $150.00
2/27/2025Piper SandlerBoost TargetOverweight ➝ Overweight$67.00 ➝ $78.00
2/27/2025HC WainwrightReiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
2/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
1/30/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$78.00 ➝ $130.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
10/18/2024Sandler O'NeillReiterated RatingBuy ➝ Buy
10/18/2024HC WainwrightBoost TargetBuy ➝ Buy$45.00 ➝ $80.00
9/30/2024Truist FinancialBoost TargetBuy ➝ Buy$65.00 ➝ $76.00
9/18/2024Piper SandlerBoost TargetOverweight ➝ Overweight$38.00 ➝ $67.00
7/30/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
7/30/2024HC WainwrightBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
7/30/2024Piper SandlerBoost TargetOverweight ➝ Overweight$35.00 ➝ $38.00
7/1/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$35.00 ➝ $35.00
6/17/2024Truist FinancialReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
6/4/2024Truist FinancialReiterated RatingBuy ➝ Buy$44.00 ➝ $65.00
5/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
5/2/2024HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $40.00
5/2/2024Truist FinancialBoost TargetBuy ➝ Buy$42.00 ➝ $44.00
4/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00
2/16/2024Truist FinancialBoost TargetBuy ➝ Buy$36.00 ➝ $42.00
1/2/2024HC WainwrightLower TargetBuy ➝ Buy$34.00 ➝ $28.00
12/13/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$37.00 ➝ $38.00
11/6/2023Truist FinancialUpgradeHold ➝ Buy$29.00 ➝ $38.00
11/2/2023HC WainwrightBoost TargetBuy ➝ Buy$32.00 ➝ $34.00
10/2/2023Truist FinancialReiterated RatingHold ➝ Hold$29.00
8/25/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$34.00 ➝ $35.00
8/3/2023Truist FinancialBoost TargetHold ➝ Hold$26.00 ➝ $29.00
8/3/2023Piper SandlerBoost TargetOverweight ➝ Overweight$27.00 ➝ $31.00
8/3/2023LADENBURG THALM/SH SHBoost Target$44.00 ➝ $47.50
8/3/2023HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $32.00
5/26/2023Truist FinancialLower Target$28.00 ➝ $26.00
4/11/2023Leerink PartnersReiterated RatingMarket Perform$25.00
4/11/2023SVB SecuritiesInitiated CoverageMarket Perform$25.00
4/4/2023Piper SandlerInitiated CoverageOverweight$27.00
3/8/2023Canaccord Genuity GroupLower TargetBuy$33.00 ➝ $32.00
3/1/2023HC WainwrightReiterated RatingBuy$30.00
2/15/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$35.00 ➝ $22.00
12/9/2022HC WainwrightLower TargetBuy$33.00 ➝ $30.00
8/9/2022Truist FinancialDowngradeHold
8/4/2022HC WainwrightBoost TargetBuy$29.00 ➝ $33.00
8/1/2022Truist FinancialDowngradeBuy ➝ Hold$30.00
7/27/2022Jefferies Financial GroupUpgradeHold ➝ Buy$21.00 ➝ $35.00
2/16/2022HC WainwrightReiterated RatingBuy$29.00
2/2/2022Canaccord Genuity GroupInitiated CoverageBuy$30.00
1/28/2022Truist FinancialInitiated CoverageBuy$30.00
7/30/2021HC WainwrightReiterated RatingBuy
6/23/2021HC WainwrightLower TargetBuy$32.00 ➝ $29.00
6/22/2021UBS GroupReiterated RatingPositive
(Data available from 5/3/2021 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/3/2026
  • 9 very positive mentions
  • 41 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
Mentions as of
2/2/2026
  • 5 very positive mentions
  • 86 positive mentions
  • 8 negative mentions
  • 6 very negative mentions
Mentions as of
3/4/2026
  • 16 very positive mentions
  • 137 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
4/3/2026
  • 8 very positive mentions
  • 75 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 8 very positive mentions
  • 75 positive mentions
  • 6 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $51.42
Low: $46.19
High: $51.66

50 Day Range

MA: $39.14
Low: $32.15
High: $46.62

52 Week Range

Now: $51.42
Low: $28.66
High: $91.00

Volume

3,274,628 shs

Average Volume

940,338 shs

Market Capitalization

$5.52 billion

P/E Ratio

146.92

Dividend Yield

N/A

Beta

0.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Corcept Therapeutics?

The following sell-side analysts have issued research reports on Corcept Therapeutics in the last year: Canaccord Genuity Group Inc., HC Wainwright, Piper Sandler, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, Wolfe Research, and Zacks Research.
View the latest analyst ratings for CORT.

What is the current price target for Corcept Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Corcept Therapeutics in the last year. Their average twelve-month price target is $72.17, suggesting a possible upside of 40.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting CORT will reach $110.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $30.00 for Corcept Therapeutics in the next year.
View the latest price targets for CORT.

What is the current consensus analyst rating for Corcept Therapeutics?

Corcept Therapeutics currently has 1 sell rating, 3 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CORT.

What other companies compete with Corcept Therapeutics?

Other companies that are similar to Corcept Therapeutics include Annovis Bio, Jazz Pharmaceuticals, Nektar Therapeutics, Supernus Pharmaceuticals and Perrigo. Learn More about companies similar to Corcept Therapeutics.

How do I contact Corcept Therapeutics' investor relations team?

Corcept Therapeutics' physical mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company's listed phone number is (650) 327-3270 and its investor relations email address is [email protected]. The official website for Corcept Therapeutics is www.corcept.com. Learn More about contacing Corcept Therapeutics investor relations.